{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:43:48Z","timestamp":1790257428013,"version":"4.1.0"},"reference-count":61,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,6,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>With modern intensive combination polychemotherapy, the complete response (CR) rate in adults with acute lymphoblastic leukemia (ALL) is 80% to 90%, and the cure rate is 40% to 50%. Hence, there is a need to develop effective salvage therapies and combine novel agents with standard effective chemotherapy. ALL leukemic cells express several surface antigens amenable to target therapies, including CD20, CD22, and CD19. Monoclonal antibodies target these leukemic surface antigens selectively and minimize off-target toxicity. When added to frontline chemotherapy, rituximab, an antibody directed against CD20, increases cure rates of adults with Burkitt leukemia from 40% to 80% and those with pre-B ALL from 35% to 50%. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has resulted in marrow CR rates of 55% and a median survival of 6 to 7 months when given to patients with refractory-relapsed ALL. Blinatumomab, a biallelic T cell engaging the CD3-CD19 monoclonal antibody, also resulted in overall response rates of 40% to 50% and a median survival of 6.5 months in a similar refractory-relapsed population. Other promising monoclonal antibodies targeting CD20 (ofatumumab and obinutuzumab) or CD19 or CD20 and bound to different cytotoxins or immunotoxins are under development. Combined modalities of chemotherapy and the novel monoclonal antibodies are under investigation.<\/jats:p>","DOI":"10.1182\/blood-2014-08-596403","type":"journal-article","created":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T22:26:10Z","timestamp":1432247170000},"page":"4010-4016","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":134,"title":["Monoclonal antibodies in acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"125","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111818422376200_B1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013.","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"2019111818422376200_B2","unstructured":"National Cancer Institute\n          SEER Stat Fact Sheet: Acute Lymphocytic Leukemia. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html. Accessed 2014"},{"issue":"6","key":"2019111818422376200_B3","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111818422376200_B4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.clml.2012.09.014","article-title":"The history of leukemia therapy\u2014a personal journey.","volume":"12","author":"Freireich","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"2019111818422376200_B5","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood leukemia without cranial irradiation.","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111818422376200_B6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial.","volume":"157","author":"Sive","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111818422376200_B7","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2019111818422376200_B8","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111818422376200_B9","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"2019111818422376200_B10","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies.","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111818422376200_B11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111818422376200_B12","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/cncr.28930","article-title":"Augmented Berlin-Frankfurt-Muenster based therapy for young adults with acute lymphoblastic leukemia (ALL).","volume":"120","author":"Rytting","year":"2014","journal-title":"Cancer"},{"issue":"7","key":"2019111818422376200_B13","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","article-title":"Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.","volume":"86","author":"Thomas","year":"1999","journal-title":"Cancer"},{"issue":"9","key":"2019111818422376200_B14","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"2019111818422376200_B15","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111818422376200_B16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/10428194.2010.529206","article-title":"Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia.","volume":"52","author":"Piccaluga","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111818422376200_B17","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2019111818422376200_B18"},{"issue":"1","key":"2019111818422376200_B19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.blre.2011.08.001","article-title":"Chemoimmunotherapy in acute lymphoblastic leukemia.","volume":"26","author":"Hoelzer","year":"2012","journal-title":"Blood Rev"},{"issue":"1","key":"2019111818422376200_B20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.12736","article-title":"Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.","volume":"165","author":"Rizzieri","year":"2014","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111818422376200_B21","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","article-title":"CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.","volume":"112","author":"Dworzak","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111818422376200_B22","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","article-title":"Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.","volume":"25","author":"Rubenstein","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111818422376200_B23","unstructured":"Clinicaltrials.gov\n          Intrathecal rituximab in lymphoid malignancies involving the central nervous system. Available at: www.clinicaltrials.gov. Accessed October 9, 2013"},{"key":"2019111818422376200_B24"},{"issue":"19","key":"2019111818422376200_B25","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.","volume":"118","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"2019111818422376200_B26","author":"Jabbour"},{"issue":"10","key":"2019111818422376200_B27","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2019111818422376200_B28","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"5-6","key":"2019111818422376200_B29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"2019111818422376200_B30","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1021\/jm060319f","article-title":"Semisynthetic maytansine analogues for the targeted treatment of cancer.","volume":"49","author":"Widdison","year":"2006","journal-title":"J Med Chem"},{"issue":"7","key":"2019111818422376200_B31","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1078-0432.CCR-12-3613","article-title":"The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.","volume":"19","author":"Carol","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2019111818422376200_B32","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.2011.39.4403","article-title":"Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed\/refractory B-cell lymphoma.","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"2019111818422376200_B33","unstructured":"Clinicaltrials.gov\n          SAR3419 in acute lymphoblastic leukemia. Available at: www.clinicaltrials.gov (NCT01440179). Accessed February 18, 2013"},{"key":"2019111818422376200_B34","article-title":"A first-in-human phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage acute leukemia and highly aggressive lymphoma [abstract].","author":"Borate","journal-title":"Blood"},{"issue":"3","key":"2019111818422376200_B35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective.","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"18","key":"2019111818422376200_B36","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111818422376200_B37","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"issue":"36","key":"2019111818422376200_B38","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111818422376200_B39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia.","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"2019111818422376200_B40","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab.","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"issue":"10 Pt 2","key":"2019111818422376200_B41","first-page":"3982S","article-title":"Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.","volume":"9","author":"Carnahan","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111818422376200_B42","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.","volume":"44","author":"Carnahan","year":"2007","journal-title":"Mol Immunol"},{"issue":"22","key":"2019111818422376200_B43","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children\u2019s Oncology Group Pilot Study.","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111818422376200_B44","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.12778","article-title":"Southwest Oncology Group Study S0910: a phase 2 trial of clofarabine\/cytarabine\/epratuzumab for relapsed\/refractory acute lymphocytic leukemia.","volume":"165","author":"Advani","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111818422376200_B45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/1535-7163.MCT-11-0632","article-title":"Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.","volume":"11","author":"Sharkey","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2019111818422376200_B46","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1517\/13543784.2012.679359","article-title":"Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia.","volume":"21","author":"Thomas","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"2019111818422376200_B47","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: results of a phase I study.","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111818422376200_B48","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111818422376200_B49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clml.2012.12.003","article-title":"Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.","volume":"13","author":"Kebriaei","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"2019111818422376200_B50","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"2019111818422376200_B51","author":"Deangelo"},{"key":"2019111818422376200_B52","article-title":"Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients and as salvage therapy for adult with relapse\/refractory acute lymphoblastic leukemia [abstract].","author":"Jabbour","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111818422376200_B53","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2019111818422376200_B54","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2008.20.2630","article-title":"Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.","volume":"27","author":"Kreitman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111818422376200_B55","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-09-2980","article-title":"Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.","volume":"16","author":"Wayne","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111818422376200_B56","first-page":"995","article-title":"Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.","volume":"8","author":"Salvatore","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2019111818422376200_B57","article-title":"A novel anti-Cd22 immunotoxin, moxetumomab pasudotox: Phase I study in pediatric acute lymphoblastic leukemia (ALL) [abstract].","author":"Wayne","journal-title":"Blood"},{"issue":"2","key":"2019111818422376200_B58","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"issue":"6","key":"2019111818422376200_B59","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/pbc.22209","article-title":"A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children\u2019s Oncology Group report.","volume":"53","author":"Angiolillo","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2019111818422376200_B60","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/sj.leu.2403422","article-title":"Remission of adult acute lymphocytic leukaemia with alemtuzumab.","volume":"18","author":"Laporte","year":"2004","journal-title":"Leukemia"},{"issue":"12","key":"2019111818422376200_B61","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cncr.21901","article-title":"Activity of alemtuzumab in patients with CD52-positive acute leukemia.","volume":"106","author":"Tibes","year":"2006","journal-title":"Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/26\/4010\/1386651\/4010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/26\/4010\/1386651\/4010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T18:42:42Z","timestamp":1574102562000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/125\/26\/4010\/34299\/Monoclonal-antibodies-in-acute-lymphoblastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,25]]},"references-count":61,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2015,6,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-08-596403","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725509021.793507803","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,25]]}}}